A major multiyear research and commercialisation deal with Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the early detection and prevention of rheumatoid arthritis*,* a debilitating autoimmune disease which affects more than 400,000 Australians 1 and more than 24.5 million people worldwide. The agreement was facilitated by Monash Innovation, part of the recently established Enterprise portfolio at Monash University, and Johnson & Johnson Innovation.
The strategic partnership is another example of Monash actively engaging with industry in order to translate its world-leading research, delivering heath and economic benefits on a global scale. The collaboration is the result of an existing productive three-year partnership with Janssen and adds to Monash University’s growing international reputation for translational research. Strong clinical relationships and early industry engagement, are leading to a pipeline of medical breakthroughs.